State of the Science Summit on Hematologic Malignancies

Seo-Hyun Kim, MD, discusses frontline treatment considerations in stage III and IV classical Hodgkin lymphoma and exciting combinations on the horizon.

Jamile M. Shammo, MD, FASCP, FACP, discusses the current treatment paradigm of myelofibrosis, criteria for ruxolitinib resistance and intolerance, and promising agents on the horizon.

Parameswaran Venugopal, MD, discusses current and emerging treatment strategies in non-Hodgkin lymphoma.

Melissa L. Larson, MD, discusses available treatments for patients with acute myeloid leukemia, as well as others that are in the pipeline.

Joseph Wynne, MD, discusses ongoing studies with blinatumomab and CAR T-cell therapy in acute lymphoblastic leukemia, as well as the importance of assessing minimal residual disease in this space.

Agne Paner, MD, discusses the treatment paradigm in multiple myeloma and promising agents on the horizon.

Alison R. Sehgal, MD, assistant professor of medicine, hematologist/medical oncologist, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, discusses the clinical implications of CAR T-cell therapy in diffuse large B-cell lymphoma (DLBCL).

Jing-Zhou Hou, MD, PhD, co-chair of the Hematological Malignancies program, and medical oncologist, hematologist, and clinical instructor at University of Pittsburgh Medical Center Hillman Cancer Center, discusses the use of polatuzumab vedotin (Polivy) in diffuse large B-cell lymphoma (DLBCL).

Jing-Zhou Hou, MD, PhD, co-chair of the Hematological Malignancies program, and medical oncologist, hematologist, and clinical instructor at University of Pittsburgh Medical Center Hillman Cancer Center, discusses the latest updates with CAR T-cell therapy in diffuse large B-cell lymphoma (DLBCL).

Robert L. Redner, MD, a medical oncologist and hematologist, and professor of medicine, at the University of Pittsburgh Medical Center Hillman Cancer Center, discusses the potency of gilteritinib (Xospata) in acute myeloid leukemia (AML).

Jing-Zhou Hou, MD, PhD, highlights the research being conducted in the realm of lymphoma, including positive and negative trials that have read out in the space, and provides insight into novel approaches under investigation.

Mounzer E. Agha, MD, discusses the approaches that are leading to prolonged survival in patients with relapsed/refractory multiple myeloma.

Anastasios Raptis, MD, a clinical assistant professor of medicine at the University of Pittsburgh School of Medicine Hillman Cancer Center, discusses the use of daratumumab (Darzalex), lenalidomide (Revlimid), and dexamethasone (DRd) in the treatment of patients with newly diagnosed multiple myeloma.

James M. Rossetti, DO, discusses strategies for symptom management, tools available for risk stratification, and updated data with some of the pivotal agents in myeloproliferative neoplasms.

Rafic Farah, MD, provides an in-depth look at the trials that now define standards of care among patients with newly diagnosed and relapsed/refractory chronic lymphocytic leukemia.

Annie Im, MD, discusses the importance of minimal residual disease in acute lymphoblastic leukemia, the role of transplant, and novel treatment approaches under investigation.

Alison R. Sehgal, MD, assistant professor of medicine, hematologist/medical oncologist, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, discusses ways to manage cytokine release syndrome (CRS) and neurotoxicity associated with CAR T-cell therapy.

Anastasios Raptis, MD, highlights promising combinations under investigation in the frontline setting and remaining challenges in multiple myeloma.

Kleber Yotsumoto Fertrin, MD, PhD, provided insight into the new options that have emerged in the treatment landscape of benign hematologic malignancies.

Robert L. Redner, MD, highlights some of the newer available agents in acute myeloid leukemia and ongoing studies that could impact clinical practice.

Alison R. Sehgal, MD, discusses the latest developments with CAR T-cell therapy in lymphomas.

Andrew J. Cowan, MD, discussed pivotal trials in multiple myeloma and potential for new treatments in the future.

Vivian G. Oehler, MD, highlights ongoing developments in myeloproliferative neoplasms and shares her hopes for the future.

Chaitra S. Ujjani, MD, discusses the various therapeutic classes and agents that are showing the most promise in the field of follicular lymphoma.

Mary-Elizabeth Percival, MD, discusses advances and challenges with targeted agents in acute myeloid leukemia and remaining questions in the field.

Mazyar Shadman, MD, MPH, discusses earlier use of CAR T-cell therapy in lymphoma, the impact of approved products on future development, and recent data with chemotherapy-free and time-limited therapy in chronic lymphocytic leukemia.

Alison Rager Sehgal, MD, assistant professor of medicine, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, discusses the structure and manufacturing process of CAR T cells.

Jerald P. Radich, MD, the methods that are used to measure minimal residual disease and the work being done to standardize its use in acute lymphoblastic leukemia.

Sameem Abedin, MD, assistant professor, Medical College of Wisconsin, discusses the role of venetoclax plus obinutuzumab in chronic lymphocytic leukemia.

Lyndsey Runaas, MD, an assistant professor at the Medical College of Wisconsin, discusses impactful targeted therapies for patients with FLT3-mutant acute myeloid leukemia (AML).